We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03056833
Recruitment Status : Completed
First Posted : February 17, 2017
Last Update Posted : September 7, 2022
Information provided by (Responsible Party):
Ronald Buckanovich, University of Pittsburgh

Brief Summary:
Investigators hypothesize that concurrent ribociclib treatment and chemotherapy will enhance the response to platinum-based therapy and maintenance therapy will slow ovarian cancer tumor growth leading to prolongation in progression free survival.

Condition or disease Intervention/treatment Phase
Ovarian Cancer Fallopian Tube Cancer Peritoneal Carcinoma Drug: ribociclib Drug: Paclitaxel Drug: Carboplatin Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 35 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Trial of Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer
Actual Study Start Date : June 10, 2017
Actual Primary Completion Date : June 1, 2020
Actual Study Completion Date : August 1, 2022

Arm Intervention/treatment
Experimental: Ribociclib
Ribociclib (LEE-011) will be used as concurrent therapy with platinum-based chemotherapy in platinum-sensitive recurrent ovarian cancer. Participants will receive 200, 400, or 600mg of ribociclib per day in combination with carboplatin + paclitaxel. Subjects will receive 6 cycles of carboplatin + paclitaxel given weekly with ribociclib.
Drug: ribociclib
Ribociclib (LEE-011) will be given on days 1-4, 8-11, and 15-18 of a 28 day cycle at 200, 400, or 600mg/day during the dose escalation phase. During the maintenance phase, ribociclib (LEE-011) will be given at 600mg/day, 3 weeks on, 1 week off until progression.

Drug: Paclitaxel
During the escalation phase Paclitaxel will be given on days 1, 8, and 15 of a 28 day cycle.

Drug: Carboplatin
During the escalation phase Carboplatin will be given on days 1, 8, and 15 of a 28 day cycle.

Primary Outcome Measures :
  1. Maximal tolerated dose (MTD) of ribociclib (LEE-011) when given with carboplatin + paclitaxel in platinum-sensitive recurrent ovarian cancer [ Time Frame: 56 days ]
    Participants will be observed for the first two treatment cycles (2, 28 day cycles) and maximum tolerated dose will be determined.

Secondary Outcome Measures :
  1. Number of participants that respond to treatment [ Time Frame: 18 months post treatment ]
    Overall response rate (ORR) will be analyzed. The number of patients that respond to treatment (exhibit Partial Response (PR) or Complete Response (CR)) will be recorded. PR is defined as at least a 50% reduction in CA 125 levels (response must be confirmed and maintained for at least 28 days) and/or at least 30% decrease in the sum diameters of target lesions. CR is defined as normalization of CA125 levels ((response must be confirmed and maintained for at least 28 days) and disappearance of all target lesions.

  2. Time from treatment until disease progression or death [ Time Frame: 18 months post treatment ]

    Progression is defined as one of the following:

    • Patients with elevated CA-125 pretreatment and normalization of CA-125 must show evidence of CA-125 greater than, or equal to, 2 times the upper limit of the reference range on 2 occasions at least 1 week apart or
    • Patients with elevated CA-125 before treatment, which never normalizes, must show evidence of CA-125 greater than, or equal to, 2 times the nadir value on 2 occasions at least 1 week apart or
    • Patients with CA-125 in the reference range before treatment must show evidence of CA-125 greater than, or equal to, 2 times the upper limit of the reference range on 2 occasions at least 1 week apart
    • Increase in at least 20% in sum of diameters of target lesions or any new lesions or unequivocal increase in non-target lesions.
    • Response determined via measurable disease (measurement of target and non-target lesions) takes precedence over CA125 criteria Stable Disease (SD): CA

  3. Number of participants encountering toxicity at each dose level [ Time Frame: 30 days post treatment ]
    Patients will potentially be treated with 3 different dose levels of ribociclib in combination with platinum-based chemotherapy.

  4. Overall Survival (OS) [ Time Frame: Up to 5 years ]
    The (median) length of time from start of treatment patients are still alive.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Women ≥18 years old
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Women ≥18 years old with platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer (defined as recurrent disease >6 months after completing last platinum-based chemotherapy) eligible to receive platinum-based doublet chemotherapy.
  2. Must have had at least 1 prior line of platinum-based therapy
  3. ECOG 0-1 with life expectancy of ≥ 3 months
  4. Adequate organ function:

    • Serum creatinine ≤1.5mg/dL or 24-hour clearance ≥50 mL/min
    • AST/ALT <2.5x ULN (or <5x ULN if liver metastasis are present)
    • Total bilirubin ≤ULN or total bilirubin ≤3.0 x ULN or direct bilirubin ≤1.5 x ULN in patients with well-documented Gilbert's Syndrome.
    • Hemoglobin ≥9 gm/dl, Platelets ≥100,000/µL, ANC ≥1500/µL
    • INR ≤1.5
    • Potassium, total calcium (corrected for serum albumin), magnesium, and sodium within normal limits for the institution or corrected to within normal limits with supplements before first dose of study medication
  5. Screening ECG (defined as the mean of the triplicate ECGs) with QTcF interval at screening ≤450msec (using Fridericia's correction) and resting heart rate 50-90bpm
  6. Must be able to swallow ribociclib (LEE-011) tablet/capsule
  7. Documented disease recurrence/progression based on GCIG-RECIST
  8. Able to provide informed consent and comply with all study protocols
  9. Treated CNS metastasis allowed if treatment is complete ≥8 weeks prior to enrollment. Patients must be asymptomatic off systemic corticosteroids for at least 4 weeks after completion of radiation therapy. CNS disease must be stable or regressed on repeat imaging performed at least 4 weeks after completion of therapy.
  10. Women of child-bearing potential (those who have had a menstrual cycle within the last year and have not had a tubal ligation or surgical removal of both ovaries and/or hysterectomy) must agree to abstain from vaginal intercourse or use and continue highly effective methods of contraception for 3 weeks after discontinuation of study treatment.
  11. Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective.

Exclusion Criteria:

  1. Borderline or low-malignant potential histology.
  2. Platinum-resistant disease (as defined as progressive disease within 6 months of completion of chemotherapy with a platinum agent)
  3. Grade 3 baseline neuropathy.
  4. Known hypersensitivity to any of the excipients of ribociclib (LEE-011), including peanuts and soy
  5. Prior use of CDK4/6 inhibitors.
  6. Congenital long QT syndrome or family history of unexpected sudden cardiac death
  7. Concurrent malignancy or malignancy within 3 years prior to starting study drug, with the exception of adequately treated basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer or per physician discretion that the previous cancer was adequately treated with curative intent and unlikely to recur (the study PI must concur with this determination).
  8. Impairment of gastrointestinal (GI) function or disease that may significantly alter the absorption of the study drugs
  9. History of HIV infection
  10. Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks and contraindicate patient's participation in the clinical study or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.).
  11. Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormalities, including any of the following:

    a. Heart Association functional classification III-IV) b. Documented cardiomyopathy c. Left Ventricular Ejection Fraction (LVEF) <50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO) at screening d. Clinically significant cardiac arrhythmias (e.g. ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g. bifascicular block, Mobitz type II and third-degree AV block) e. Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome, or any of the following: i. Risk factors for Torsades de Pointe (TdP) including uncorrected hypokalemia or hypomagnesaemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia.

    ii. Concomitant use of medication(s) with a known risk to prolong the QT interval and/or known to cause Torsades de Pointe that cannot be discontinued (within 5 half-lives or 7 days prior to starting study drug) or replaced by safe alternative medication iii. Inability to determine the QT interval on screening (QTcF using Fridericia's correction) f. Systolic blood pressure (SBP) >160 mmHg or <90 mmHg at screening g. History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or symptomatic pericarditis within 6 months prior to screening

  12. Use of prohibited medications (see section 5.3) that cannot be changed to an alternative therapy
  13. Patient is currently receiving or has received systemic corticosteroids ≤2 weeks prior to starting study drug, or who have not fully recovered from side effects of such treatment.

    a. The following uses of corticosteroids are permitted: single doses, topical applications (e.g., for rash), inhaled sprays (e.g., for obstructive airways diseases), eye drops or local injections (e.g., intra-articular)

  14. Patient is currently receiving warfarin or other coumadin-derived anticoagulant for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowed.
  15. Use of herbal supplements unless discontinued ≥7 days prior to initiation of study drug
  16. Consumption of foods which are strong inducers or inhibitors of CYP3A4/5 has to be discontinued 7 days prior to initiation of study drug
  17. Pregnancy or lactation
  18. Participation in a prior investigational study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer
  19. Patient who has received radiotherapy ≤4 weeks or limited field radiation for palliation ≤2 weeks prior to starting study drug, and who has not recovered to grade 1 or better from related side effects of such therapy (exceptions include alopecia) and/or in whom ≥25% of the bone marrow (Ellis, 1961) was irradiated.
  20. Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery).
  21. Patient has not recovered from all toxicities related to prior anticancer therapies to NCI-CTCAE version 5 Grade ≤1 (Exception to this criterion: patients with any grade of alopecia and/or neuropathy ≤ grade 2 are allowed to enter the study).
  22. Patient with a Child-Pugh score B or C.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03056833

Layout table for location information
United States, Michigan
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States, 48109
United States, Pennsylvania
UPMC Hillman Cancer Center Upper St. Clair
Bethel Park, Pennsylvania, United States, 15102
UPMC Hillman Cancer Center Arnold Palmer at Mountain View
Greensburg, Pennsylvania, United States, 15601
UPMC Hillman Cancer Center Arnold Palmer Medical at Norwin
Irwin, Pennsylvania, United States, 15642
UPMC Hillman Cancer Center Arnold Palmer at Mt Pleasant
Mount Pleasant, Pennsylvania, United States, 15666
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
UPMC Hillman Cancer Center Passavant (OHA)
Pittsburgh, Pennsylvania, United States, 15237
UPMC Hillman Cancer Center Washington
Washington, Pennsylvania, United States, 15301
Sponsors and Collaborators
Ronald Buckanovich
Layout table for investigator information
Principal Investigator: Lan G Coffman, M.D. University of Pittsburgh Medical Center
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ronald Buckanovich, Professor, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT03056833    
Other Study ID Numbers: 18-006
CLEE011XUS28T ( Other Identifier: Novartis, Inc )
First Posted: February 17, 2017    Key Record Dates
Last Update Posted: September 7, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Fallopian Tube Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Fallopian Tube Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action